Search

Your search keyword '"Matthews, Gail V"' showing total 602 results

Search Constraints

Start Over You searched for: Author "Matthews, Gail V" Remove constraint Author: "Matthews, Gail V"
602 results on '"Matthews, Gail V"'

Search Results

1. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

2. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

4. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

6. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

10. Reinfection incidence and risk among people treated for recent hepatitis C virus infection

11. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

14. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

15. Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023).

17. Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

18. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

19. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

22. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

23. Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020

24. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

25. Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)]

27. Cure and Control: What Will It Take to Eliminate HCV?

28. Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study

30. Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020

31. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

32. Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population‐based study.

33. The APPRISE Virtual Biobank for Infectious Diseases

34. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

35. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

37. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

38. A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015

39. Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study

40. Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia

44. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era

46. The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC

47. Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population‐based study

Catalog

Books, media, physical & digital resources